{"id":"W2139672588","doi":"10.1111/j.1600-6143.2012.04127.x","title":"Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year","year":2012,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Yonsei University College of Medicine; Baylor University Medical Center; Cilag; Astellas Pharma; Seoul National University Hospital; Seoul National University; Yonsei University; University of South Carolina; University of Arkansas for Medical Sciences; Amgen; Baylor University; Universidade de Coimbra; Yale University; Erasmus Medisch Centrum; Cedars-Sinai Medical Center; Northwestern University; Pfizer; Feinberg School of Medicine; University of Alberta; Bristol-Myers Squibb","keywords":"Medicine; Basiliximab; Tofacitinib; Janus kinase inhibitor; Internal medicine; Renal function; Gastroenterology; Urology; Transplantation; Chronic allograft nephropathy; Kidney transplantation; Mycophenolic acid; Neutropenia; Surgery; Chemotherapy; Rheumatoid arthritis","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00128134,0.001484342,0.001713127,0.000345091,0.0002417718,0.0008313511,0.0005908078,0.0009422999,0.005424174],"category_scores_gemma":[0.0008075336,0.0004659405,0.0009040371,0.0002524602,0.0005306876,0.0006319176,0.0002897263,0.002052503,0.0007751217],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006881262,"about_ca_system_score_gemma":0.0008324379,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007014243,"about_ca_topic_score_gemma":0.00159552,"domain_scores_codex":[0.9997405,0.0001227293,0.00001283245,0.00004869967,0.00002486496,0.00005019603],"domain_scores_gemma":[0.999491,0.00009927346,0.0001318221,0.00003737182,0.0000251819,0.0002154903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9540914,0.0101488,0.002360084,0.0002663535,0.0006728232,0.00005674105,0.00003969574,0.0004537953,0.007312314,0.000143906,0.0009515822,0.02350245],"study_design_scores_gemma":[0.9217902,0.07109113,0.005052241,0.00001551719,0.0002966004,0.00008038538,0.00001215498,0.0004363622,0.0005510565,0.0001012295,0.0005621717,0.00001094169],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943345,0.001391407,0.0004223481,0.0002787693,0.0001009789,0.001409541,0.000877874,0.0000754218,0.001109188],"genre_scores_gemma":[0.988443,0.0014945,0.001563531,0.001014861,0.0002720255,0.002425337,0.002304008,0.00001900936,0.002463588],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005424174,"threshold_uncertainty_score":0.01814568,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01422037986658146,"score_gpt":0.296094047945285,"score_spread":0.2818736680787035,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}